Background/Aims: VEGF-A is induced by oxidative stress, and functions as a survival factor for various cell types, including retinal pigment epithelial (RPE) cells. Anti-vascular endothelial growth factor (VEGF) drugs like aflibercept and bevacizumab have shown to be most effective in treating neovascular age-related macular degeneration (AMD), however uptake of the drugs might lead to interference with cell physiology. Herein, we evaluated the significance of the Fc receptor (FcR) within this context and moreover explored the impact of VEGF inhibition under normal conditions as well as under oxidative stress, in terms of potential adverse effects. Methods: ARPE-19 (human RPE) cells were treated with aflibercept and bevacizumab in presence or absence of H 2 O 2 as oxidative stress stimulus. After 24h cells were evaluated for drug uptake, VEGF-A expression and secretion, levels of intracellular reactive oxygen species (ROS) as well as cell proliferation. Experiments were repeated with cells being pre-incubated with an FcR inhibitor prior to drug application. Results: Both drugs inhibited extracellular levels of VEGF-A and were taken up into the RPE, resulting in significantly reduced intracellular levels of VEGF-A. When oxidative stress was applied, intracellular ROS levels in cells treated with both drugs rose, and cell proliferation was reduced. Prior incubation with the FcR inhibitor lessened the uptake of bevacizumab, but not aflibercept into RPE cells, and simultaneously enhanced cell survival under oxidative stress conditions. Conclusions: Our results indicate that uptake and accumulation of aflibercept and bevacizumab within RPE cells affect the intracellular VEGF-A metabolism negatively, leading to a biologically relevant reduced cell survival under oxidative stress. The FcR plays a substantial role in the uptake of bevacizumab, M. Rudolf and S. Grisanti contributed equally to this work and should be regarded as equivalent senior authors.
Introduction
Vascular endothelial growth factor A (VEGF-A) is an important regulator of angiogenesis, which acts as an autocrine growth and survival factor in VEGF-A-producing cells [1] . VEGF-A induces phosphorylation of VEGF receptor 2 (VEGFR-2) thereby activating downstream signaling, which results in migration, proliferation and survival [2] .
Pathologic VEGF-A/VEGFR-2-mediated neovascularization plays a significant role in different sight-threatening ocular diseases like neovascular age-related macular degeneration (NVAMD) [3] .
Retinal pigment epithelial (RPE) cells have been disclosed to be the main source of NVAMD-related VEGF-A and especially the cells of the macular region in AMD patients show an increased expression of VEGF-A [4] . Oxidative stress, caused by reactive oxygen species (ROS) such as superoxide or hydrogen peroxide (H 2 O 2 ), has been described to promote the deposition of oxidized proteins in Bruch's membrane, provoking pro-angiogenic VEGF-A release from the RPE [5, 6] . Cellular damage resulting from oxidative stress might play a key role in aging of the RPE, and oxidative stress-induced apoptosis has been suggested as an important pathophysiological mechanism of AMD [7] .
Intravitreal anti-VEGF therapy with drugs like aflibercept and bevacizumab has greatly improved vision prognosis of NVAMD patients and has been shown to be the most effective treatment so far [8] [9] [10] . Whilst aflibercept is a recombinant fusion protein consisting of the VEGF binding domain 2 of VEGF receptor 1 (VEGFR-1), the binding domain 3 of VEGFR-2 and an IgG-Fc part, bevacizumab is a full-length humanized antibody [11, 12] . In addition to VEGF-A, aflibercept inhibits VEGF-B and placental growth factor (PlGF), which bevacizumab does not [12, 13] .
Recent clinical trials suggest that the RPE may degenerate and perish through longterm anti-VEGF treatment, causing larger areas of geographic atrophy (GA) [14, 15] . The reason might lay in a broad inhibition of VEGF-A activity, since it is a survival factor for the developing and mature retina, or it could be the result of drug-mediated direct cellular damage [3, 16, 17] .
Intracellular uptake of anti-VEGF drugs, damaging the cells directly from within, has been suggested as a possible reason for RPE degeneration and subsequent GA [18, 19] . This drug taken up into the cells assumingly affects the physiology of the cells like reduced phagocytic capacity and interference with protein synthesis [19, 20] .
The Fc receptor (FcR) is a cellular protein, which binds the Fc region of immunoglobulin G (IgG). It protects IgG from catabolism, controls its transport between cell layers and extends its serum half-life [21] . Expression of FcR on RPE cells and its involvement in processing vitreous IgG has already been shown [22] [23] [24] [25] . However, a potential interaction with anti-VEGF drugs has not been elucidated, yet.
Therefore, in this study we aimed to evaluate the role of FcR in intracellular uptake of aflibercept and bevacizumab. Moreover, we looked into the impact of VEGF inhibition under normal conditions as well as under oxidative stress with regard to VEGF-A expression/ secretion, generation of intracellular ROS and cell proliferation. At last, we assessed the influence of inhibiting the FcR under these circumstances to expose potential clinically relevant therapeutic approaches in diseases like AMD.
Immunofluorescence Cells were washed with PBS and fixated in paraformaldehyde (4%). Samples were permeabilized and blocked in 0.1% Triton/5% goat serum in PBS for 2 h at room temperature (RT), and incubated with a rabbitanti-human Rab5 (early endosome marker) or VEGF-A antibody (both 1:200; Perbio Science) overnight at 4°C. After another wash with PBS, samples were incubated with a mixture of Alexa488-conjugated-mouseanti-rabbit fluorescent secondary antibody (1:150; Merck Millipore) and 4', 6-diamidino-2-phenylindole (DAPI; 1:100; Life Technologies, Darmstadt, Germany) for 1h at RT. The coverslips were mounted on slides using Mowiol mounting medium (Sigma Aldrich, Steinheim, Germany), and images were taken with a confocal fluorescence microscope (LSM 510 META, Carl Zeiss, Jena, Germany) or an inverse fluorescence microscope (Leica DMI6000 B, Leica Microsystems, Wetzlar, Germany).
To evaluate drug uptake, three confocal fluorescence images were taken of each cover slip and analyzed for co-localized Dylight650/Alexa488 (drug/Rab5) particles, which resembled the drug taken up into the cells, and evaluation was performed semi-quantitatively using ImageJ software (NIH, Bethesda, USA).
To assess intracellular VEGF production, three inverse fluorescence images were taken of each cover slip and analyzed by semi-quantitative measurement of Alexa488 (VEGF-A) particles around DAPI-positive cell nuclei, once again using ImageJ software. The number of particles was normalized to the count of cell nuclei in each image.
Finally, to evaluate cell proliferation, three inverse fluorescence images were captured of each cover slip and analyzed by counting the number of DAPI-positive cell nuclei using ImageJ software.
Detection of extracellular VEGF-A
Cell culture supernatants at the indicated time point were analyzed for VEGF-A (all isoforms) by ELISA (R&D Systems, Minneapolis, MN, USA) using a multimode plate reader (SpectraMax M4, Molecular Devices, Biberach an der Riß, Germany), according to the manufacturer's protocol.
Detection of ROS
Cells were washed twice with PBS and 10 µM CM-H 2 DCFDA (Molecular Probes, Paisley, UK) was applied for 15 min. CM-H 2 DCFDA is a chloromethyl derivative of H 2 DCFDA, and serves as an indicator of ROS in cells. CM-H 2 DCFDA passively diffuses into cells, where its acetate groups are cleaved by intracellular esterases and its thiol-reactive chloromethyl group reacts with intracellular glutathione and other thiols. Subsequent oxidation yields a fluorescent adduct that is trapped inside the cell. Thus, ROS levels were measured using a multimode plate reader (SpectraMax M4), according to the manufacturer's protocol. ROS levels were normalized to the number of cells as determined in the cell proliferation assay.
Results

Short-tandem repeat (STR) analysis
The analysis was performed to proof the authenticity of the cells. The STR profile (D5, D13, D7, D16, vWA, TH1, TPOX, CSF1) showed matches of respective parental reference cell lines as indicated by a search of the database of cell banks ATCC (USA), JCRB (Japan), RIKEN (Japan), KCLB (Korea), Wistar Institute (USA) and DSMZ ( Fig. 1) . Therefore, the cells utilized for this study were taken from authentic RPE cell cultures.
Evaluation of drug uptake
For evaluation of intracellular drug uptake, human IgG was used as an equimolar whole molecule control (Fig. 2 ). Aflibercept as well as bevacizumab showed significantly less uptake than their equimolar IgG control (* p < 0.001). Furthermore it seemed that considerably more aflibercept was taken up into the cells compared to bevacizumab. Application of the FcR inhibitor resulted in significantly less uptake of human IgG and bevacizumab (** p < 0.0001 for both IgG concentrations and **p=0.00016 for bevacizumab), but not aflibercept (p = 0.1281).
Effects of anti-VEGF drugs and FcR blockage on intracellular VEGF-A
Intracellular VEGF-A was assessed by semi-quantitative analysis of immunofluorescence image for VEGF-A (Fig. 3) . Incubation with aflibercept and bevacizumab reduced the amount of VEGF-A within the RPE cells significantly (* p < 0.01 for both). This effect could be weakened by the FcR inhibitor for bevacizumab (** p = 0.0310), but not in case of aflibercept (p = 0.3228). H 2 O 2 exposure resulted in a significant increase of VEGF-A produced within the cells (° p < 0.0001), which was significantly reduced by both aflibercept and bevacizumab (^ p < 0.01). However, incubation with the FcR inhibitor prior to bevacizumab exposure decreased this inhibitory effect (°* p = 0.00013), resulting in a significant increase of VEGF-A, but it was not the case with aflibercept (p = 0.3388).
Effects of anti-VEGF drugs and FcR blockage on extracellular VEGF-A
Extracellular levels of VEGF-A were evaluated by ELISA (Fig. 4) . Incubation with aflibercept and bevacizumab significantly reduced the amount of VEGF-A in the supernatant (* p < 0.00001). Aflibercept inhibited VEGF-A significantly stronger than bevacizumab (** p < 0.001). H 2 O 2 increased the secretion of VEGF-A into the supernatant compared to standard conditions (° p < 0.00001), which was completely inhibited by both aflibercept and bevacizumab (^ p < 0.00001). The use of the FcR inhibitor solution had no statistically measurable significance in this setting.
Effects of anti-VEGF drugs and FcR blockage on generation of reactive oxygen species (ROS)
The measurement of ROS was performed using a CM-H 2 DCFDA assay (Fig. 5) . Application of H 2 O 2 resulted in a significant increase of intracellular ROS levels for all agents (° p < 0.0001). This increase of ROS was amplified by both aflibercept and bevacizumab (** p < 0.01). Pre-incubation of the FcR inhibitor reduced bevacizumab-induced ROS increase partially, but significantly (* p = 0.04651). However, it was not the case with aflibercept (p = 0.2739) once again. 
The FcR inhibitor resulted in a significantly reduced uptake of IgG and bevacizumab, but not aflibercept (**). */** Signifies p < 0.05 (unpaired Student t test).
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Effects of anti-VEGF drugs and FcR blockage on cell proliferation
Cell proliferation was evaluated by counting of the DAPI-stained cell nuclei (Fig. 6 ). Under normal conditions neither of the drugs had a negative effect on proliferation of RPE cells. Oxidative stress (H 2 O 2 ) led to a significant decrease in cell proliferation (* p < 0.0001), and both aflibercept and bevacizumab significantly augmented this anti-proliferative effect (*** p = 0.00035 for aflibercept and p = 0.00038 for bevacizumab). However, when the FcR inhibitor was applied in advance, this drug-induced augmentation was significantly attenuated in cells exposed to bevacizumab (** p = 0.00028), but not in cells exposed to aflibercept (p = 0.3326).
Discussion
During recent years it emerged that increasing oxidative stress plays a significant role in the pathogenesis of AMD and aging in general [26] . In various cells, VEGF-A expression is triggered through oxidative stress and functions as an autocrine survival factor [27, 28] . Several mechanisms have been elaborated to explain the protective effect mediated by VEGF-A against oxidative stress [29, 30] .
In RPE cells, Akt signaling has been suggested to counteract oxidative injury and to prevent apoptotic cell death [31] . Blocking PI3K-Akt significantly enhances H 2 O 2 -induced (ROS) levels. Results were normalized to the control under standard conditions. H 2 O 2 led to significant increase in the accumulation of ROS for all tested substrates (°). Both aflibercept and bevacizumab enhanced H 2 O 2 -mediated intracellular ROS levels (**). However, applying the FcR inhibitor significantly reduced the amplification through bevacizumab (*), but not aflibercept. °/*/** Signifies p < 0.05 (unpaired Student t test). Results were normalized to the control under standard conditions. H 2 O 2 reduced the number of cells significantly for all tested agents (*). Applying aflibercept and bevacizumab aggravated the anti-proliferative effect under oxidative stress (***). Yet, prior incubation with the FcR inhibiting solution softened that effect significantly in cells exposed to bevacizumab (**), but not in cells exposed to aflibercept. */**/*** Signifies p < 0.05 (unpaired Student t test).
RPE cell apoptosis and cell death. Autocrine VEGF-A signaling has been postulated to affect the Akt signaling pathway, which may be used by RPE cells to survive under conditions of oxidative stress [28] .
The accumulation of aflibercept and bevacizumab within the cells led to a decrease in VEGF-A expression and protein synthesis. Another group has described this kind of intracellular impact for bevacizumab previously, which is consistent with our current results [18, 32] .
Under normal conditions clinical dosages of aflibercept and bevacizumab have shown almost no toxic effect on RPE cells [17] . This might implicate that the aforementioned decreased VEGF-A expression within the cells and the blocked reactive autocrine survival mechanisms do not have any biological relevance under these circumstances. However, under conditions of higher oxidative stress, RPE cell proliferation and cell survival was significantly reduced. Similar results have been achieved by others with regard to retinal ganglion cells, in which bevacizumab neutralized the protective effect of VEGF-A [33] .
Accumulation of intracellular ROS is a major source of oxidative stress in AMD [34] . H 2 O 2 induced a significant increase of intracellular ROS. Interestingly, this effect was even stronger in presence of aflibercept and bevacizumab, which might support the suggestion that these drugs promote the susceptibility of RPE cells to oxidative stress.
The most remarkable finding of our in vitro study was the significance of the FcR in drug uptake into RPE cells and subsequent cellular functions. Our data support the suggestion that the FcR mediates the uptake of bevacizumab resulting in less harmful adverse effects at high levels of oxidative stress. However, this could not be reproduced for aflibercept, which may be due to pharmacological properties of the fusion protein.
It has been proposed that accumulated aflibercept and bevacizumab additionally inhibit intracellular pathways of VEGF-A expression [32] . Therefore, reduced uptake into RPE cells mediated by blockage of the FcR could allow the cells to produce VEGF-A to an adequate extent. Indeed, applying the FcR blocking solution led to a significant increase in the amount of VEGF-A produced within the cells when bevacizumab was applied under normal conditions and especially at high levels of oxidative stress. This significant elevation of intracellular VEGF-A levels seemingly had an actual biological relevance as RPE cell proliferation and cell survival benefited clearly.
Extracellular levels of VEGF-A did not change significantly through application of the FcR inhibitor. However, the beneficial effect of FcR inhibition with regard to cell survival could be due to less interference with the intracellular production of VEGF-A leading to more secretion. Extracellular VEGF-A in the supernatant was blocked by bevacizumab, so that a significant increase in total VEGF-A was not measurable by our methods. Yet, a significantly higher extracellular concentration of VEGF-A close-by the cells could be expected, which may activate autocrine survival pathways via VEGFR-2/PI3K-Akt [28, 35] . Another explanation could be an intracrine survival loop mechanism of VEGF-A and its receptors to promote cell survival as shown for other cell types [36] [37] [38] .
In addition, intracellular ROS levels were significantly lower when the FcR inhibitor was applied prior to bevacizumab. This could be explained by higher autocrine stimulation of specific pathways through VEGF-A encouraging antioxidant defense enzymes [39] .
Different from bevacizumab, aflibercept was not affected by the FcR blockage with regard to its uptake, and the subsequent protective aspects seen as in bevacizumab-treated cells were not detected. This may further strengthen our hypothesis that intracellular anti-VEGF drugs may directly affect RPE cell survival through its VEGF inhibitory effect.
Our results indicate that inhibition of VEGF-A signaling with anti-VEGF drugs as aflibercept and bevacizumab may negatively effect RPE cell survival in AMD eyes, which is crucial for visual recovery. VEGF-A may have a beneficial effect in assisting RPE cell resistance against oxidative stress. It may therefore be important to modulate the extent of VEGF-A blockade, when considering VEGF-A inhibition as a treatment strategy. Especially since clinical trials already suggest that the RPE could degenerate and perish through anti-VEGF treatment, resulting in an increased incidence and progression of geographic atrophy [15] .
These adverse effects of anti-VEGF treatment were also reported when ranibizumab was used for treatment in AMD patients [14] . Ranibizumab is a Fab-fragment inhibiting VEGF-A [40] . Its higher affinity to VEGF-A as well as its smaller frame could be the reason for more severe atrophic changes compared to bevacizumab [13] . Furthermore the molecule doesn't carry an Fc-fragment, which indicates that other mechanisms may be involved.
The current results suggest that inhibition of the FcR on RPE cells might be a potential way to reduce the risk of RPE cell death through intracellular VEGF-A inhibition by bevacizumab. Further investigations are necessary in order to elucidate the role of the FcR for RPE cell physiology, and the mechanisms through which the tested drugs inhibit VEGF-A expression intracellularly.
Most of the published data regarding pharmacodynamics of anti-VEGF drugs in RPE cells have been obtained from primary animal RPE cells or from primary human RPE cells [32, 41, 42] . Although the phenotype of cultured RPE has been shown to be somewhat different from in vivo RPE cells, the properties of primary RPE cultures are considered to be very similar to RPE cells in vivo [43] . Considering that anti-VEGF drugs, when applied in AMD, are injected into eyes with diseased RPE cells, it should be strongly taken into account that the use of healthy primary RPE might not be an adequate approach for clinical translation. In our study we decided to use ARPE-19 cells, because the hypersensitivity to VEGF action, loss of pigmentation, and weaker tight junctions, are all properties which somewhat resemble the aged eye or pathologic conditions [44, 45] . However, ARPE-19 cells have certain limitations like reduced phagocytotic capacity, low expression of several RPE markers and the inability to metabolize vitamin A [43, 46] . Therefore, results should be interpreted with caution.
In summary, we could show that the intracellular uptake of bevacizumab, but not of aflibercept, is significantly mediated by the FcR in cultured ARPE-19 cells, and that the inhibition of intracellular uptake of bevacizumab might increase RPE cell survival rate under oxidative stress condition.
